Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanomaMichele Maio, Paolo A. Ascierto, Virginia Picasso et al.|Annals of Oncology|2013Cited by 141
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II studyAnna Maria Di Giacomo, Michele Maio, Paolo A. Ascierto et al.|Annals of Oncology|2014Cited by 139
A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial.Anna Maria Di Giacomo, Michele Maio, Diego Annesi et al.|Journal of Clinical Oncology|2015Cited by 8
1081MO Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trialAnna Maria Di Giacomo, Michele Maio, Michele Del Vecchio et al.|Annals of Oncology|2020Cited by 7
Efficacy and safety data from elderly patients with pretreated advanced melanoma in the Italian cohort of ipilimumab expanded access programme (EAP).Vanna Chiarion‐Sileni, Paola Queirolo, Jacopo Pigozzo et al.|Journal of Clinical Oncology|2013Cited by 5